1. Home
  2. SOWG vs JAGX Comparison

SOWG vs JAGX Comparison

Compare SOWG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$0.44

Market Cap

5.1M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.41

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
JAGX
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.0M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
SOWG
JAGX
Price
$0.44
$0.41
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
1.5M
495.0K
Earning Date
03-20-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
32.20
N/A
EPS
N/A
N/A
Revenue
$31,992,511.00
$11,689,000.00
Revenue This Year
$6.81
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
99.07
19.75
52 Week Low
$0.23
$0.40
52 Week High
$2.12
$15.48

Technical Indicators

Market Signals
Indicator
SOWG
JAGX
Relative Strength Index (RSI) 49.04 34.38
Support Level $0.38 N/A
Resistance Level $0.47 $0.69
Average True Range (ATR) 0.07 0.07
MACD 0.01 -0.01
Stochastic Oscillator 32.28 3.15

Price Performance

Historical Comparison
SOWG
JAGX

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: